Inxmed (Shanghai) Co., Ltd
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-11-10
- Employees
- -
- Market Cap
- -
- Website
- http://www.inxmed.com
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06166836
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳First Affiliated Hospital of Bengbu Medical College, Bengbu, China
🇨🇳Hunan Cancer Hospital, Changsha, China
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06030258
- Locations
- 🇨🇳
Shandong Province Cancer Hospital, Jinan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, China
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer Recurrent
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06014528
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05994131
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
IN10018 Combination Therapy in Previously-treated Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05982522
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Drug: IN10018+PLDDrug: IN10018+PLD+Toripalimab
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05830539
- Locations
- 🇨🇳
Anyang Tumor Hospital, Anyang, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT05827796
- Locations
- 🇨🇳
Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Drug: IN10018 in combination with PLD
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05551507
- Locations
- 🇨🇳
Anyang Cancer Hospital, Anyang, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, China
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05327231
- Locations
- 🇨🇳
Anyang Tumor Hospital, Anyang, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04109456
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center., Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States